Investor Toolbox
Listen to Call
Recording not yet available.
Read Transcript
Transcript not yet available.
View Infographic
Infographic not yet available.
MRK Coverage
Event
Merck & Co., Inc. (MRK) European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
Apr 2, 2026
Event
Merck & Co., Inc. (MRK) Q1 2026 Earnings Call
Apr 1, 2026
Event
Merck & Co., Inc. (MRK) Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
Mar 30, 2026
Transcript
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript
Feb 4, 2026
Transcript
Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript
Jan 22, 2026
Transcript
Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript
Jan 22, 2026
News
Key highlights from Merck’s (MRK) Q3 2025 earnings results
Oct 30, 2025
News
Infographic: How Merck (MRK) performed in Q3 2024
Oct 31, 2024